title: Activation of smooth muscle alpha-actin promoter in ras-transformed cells by treatments with antimitotic agents: correlation with stimulation of SRF:SRE mediated gene transcription.
abstract: Smooth muscle alpha-actin promoter is repressed in ras-transformed fibroblast cells and derepressed in revertant cells. We have recently shown that serum response factor (SRF) which can bind to the serum response elements (SREs) present in the alpha-actin promoter, can activate alpha-actin promoter activity in ras-transformed cells and suppress transformation by ras. Agents that stimulate SRF expression and alpha-actin promoter activity in ras-transformed cells are expected to be potential candidates as antitumor agents. In this study, we show that treatment of ras-transformed cells with antitumor agents such as taxol, vincristine, vinblastine, colchicine, and nocodazole leads to 5- to 7-fold activation of alpha-actin promoter driven CAT activity, whereas there was very little effect on thymidine kinase promoter driven CAT activity. This activation occurred at subcytotoxic concentrations of these agents and correlated with inhibition of cell cycle progression. Furthermore, these agents stimulated SRF expression in ras-transformed cells, as measured by its SRE binding activity. The increase in alpha-actin expression is accompanied by the restoration of actin filaments into organized bundles. These results suggest a novel mechanism by which antimitotic agents suppress the ras-transformed phenotype.
authors.affiliation: Department of Tumor Biology, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.
authors.forename: C C
authors.initials: CC
authors.lastname: Kumar
authors.forename: J H
authors.initials: JH
authors.lastname: Kim
authors.forename: P
authors.initials: P
authors.lastname: Bushel
authors.forename: L
authors.initials: L
authors.lastname: Armstrong
authors.forename: J J
authors.initials: JJ
authors.lastname: Catino
mesh_terms: D008841:Actin Cytoskeleton / Q000187:drug effects / Q000648:ultrastructure; D000199:Actins / Q000096:biosynthesis* / Q000235:genetics*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001483:Base Sequence; D002460:Cell Line; D002461:Cell Line, Transformed; D015500:Chloramphenicol O-Acetyltransferase / Q000096:biosynthesis; D003078:Colchicine / Q000494:pharmacology; D016384:Consensus Sequence; D017931:DNA Primers; D004268:DNA-Binding Proteins / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D011905:Genes, ras; D006801:Humans; D008969:Molecular Sequence Data; D009130:Muscle, Smooth / Q000378:metabolism; D015739:Nocodazole / Q000494:pharmacology; D009838:Oligodeoxyribonucleotides; D017239:Paclitaxel / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic; D051381:Rats; D013937:Thymidine Kinase / Q000096:biosynthesis / Q000235:genetics; D014158:Transcription, Genetic / Q000187:drug effects; D014162:Transfection; D014747:Vinblastine / Q000494:pharmacology; D014750:Vincristine / Q000494:pharmacology; D014982:Xenopus laevis
chemical_list: D000199:Actins; D000970:Antineoplastic Agents; D017931:DNA Primers; D004268:DNA-Binding Proteins; D009838:Oligodeoxyribonucleotides; D014750:Vincristine; D014747:Vinblastine; D015500:Chloramphenicol O-Acetyltransferase; D013937:Thymidine Kinase; D017239:Paclitaxel; D015739:Nocodazole; D003078:Colchicine